NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBYI shares have increased by 7.5% and is now trading at $9.9650. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 4 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology.

Puma Biotechnology Inc (NASDAQ:PBYI) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.34. The biopharmaceutical company had revenue of $51.20 million for the quarter, compared to analyst estimates of $44.42 million. Puma Biotechnology had a negative net margin of 36.72% and a negative return on equity of 500.98%. The company's revenue was down 48.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.21 earnings per share. View Puma Biotechnology's earnings history.

11 brokerages have issued 12 month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's stock price to reach $12.22 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price. View analysts' price targets for Puma Biotechnology.

News headlines about PBYI stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Puma Biotechnology earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Puma Biotechnology.

Puma Biotechnology saw a decline in short interest in June. As of June 15th, there was short interest totaling 7,440,000 shares, a decline of 5.6% from the May 31st total of 7,880,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 6.4 days. Approximately 22.4% of the shares of the company are short sold. View Puma Biotechnology's Current Options Chain.

Some companies that are related to Puma Biotechnology include Akebia Therapeutics (AKBA), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), BELLUS Health (BLUSF), Epizyme (EPZM), Zymeworks (ZYME), MacroGenics (MGNX), INDIVIOR PLC/S (INVVY), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), Revance Therapeutics (RVNC), Innoviva (INVA), Passage Bio (ZNTL) and Portola Pharmaceuticals (PTLA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.46%) and Envestnet Asset Management Inc. (0.05%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt, Jay M Moyes, Richard Paul Bryce and Troy Edward Wilson. View institutional ownership trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Richard Paul Bryce, and Troy Edward Wilson. View insider buying and selling activity for Puma Biotechnology.

PBYI stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd. View insider buying and selling activity for Puma Biotechnology.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $9.97.

Puma Biotechnology has a market capitalization of $392.26 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]